MedPath

Gentamicin

Generic Name
Gentamicin
Brand Names
Gentak, Pred-G, Valisone-G
Drug Type
Small Molecule
Chemical Formula
C60H123N15O21
CAS Number
1403-66-3
Unique Ingredient Identifier
T6Z9V48IKG

Overview

Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects. Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.

Background

Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects. Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.

Indication

1.本品适用于敏感铜绿假单胞菌、变形杆菌(吲哚阳性和阴性)属、大肠埃希菌、克雷伯菌属、肠杆菌属、沙雷菌属、柠檬酸杆菌属以及葡萄球菌属(不包括耐甲氧西林菌株)所致的严重感染;临床上本品常与β内酰胺类或其他抗菌药物联合应用。本品与青霉素G(或氨苄西林)联合应用治疗肠球菌感染; 2.本品用于铜绿假单胞菌或葡萄球菌属所致的严重中枢神经系统感染(如脑膜炎、脑室炎)时,可同时用本品鞘内注射作为辅助治疗; 3.本品不适用于单纯性尿路感染初治,除非病原菌对其他毒性较低的抗菌药物不敏感,本品对链球菌属中多数菌种(尤其D组)、肺炎链球菌和厌氧菌(如拟杆菌属或梭状芽孢杆菌属)无效; 4.本品口服可用于肠道感染或结肠手术前准备,也可用本品肌注合并克林霉素或甲硝唑以减少结肠手术后感染率。 5.局部外用适用于治疗敏感细菌所致的外眼感染,如结膜炎、结膜炎、泪囊炎、睑缘炎、睑板腺炎等。

Associated Conditions

  • Allergic Conjunctivitis (AC)
  • Bacterial Conjunctivitis
  • Bacterial Infections
  • Bacterial Keratitis
  • Bacterial Peritonitis
  • Bacterial dacryocystitis
  • Blepharoconjunctivitis
  • Central Nervous System Infections
  • Corneal infection
  • Dermatitis infected
  • Ecthyma
  • Eczematous dermatitis infected
  • Folliculitis
  • Furunculosis
  • Gram-negative enteric bacilli neonatal sepsis
  • Impetigo contagious
  • Inflammation
  • Keratoconjunctivitis
  • Meibomianitis
  • Meningitis, Bacterial
  • Ocular Inflammation
  • Pustular Psoriasis (PP)
  • Pustular acne
  • Pyoderma Gangrenosum
  • Seborrheic Dermatitis
  • Septicemia gram-negative
  • Skin Infections
  • Skin and Subcutaneous Tissue Bacterial Infections
  • Sycosis barbae
  • Bacterial blepharitis
  • Bacterial corneal ulcers
  • Bacterial skin infections
  • Complicated Respiratory tract infection bacterial
  • Complicated Urinary Tract Infection caused by susceptible bacteria
  • Corticosteroid-responsive dermatoses
  • Ocular bacterial infections
  • Severe Endocarditis enterococcal
  • Severe Infection Pseudomonas aeruginosa
  • Severe Staphylococcal infection

Clinical Trials

Phase 4
Not yet recruiting
Posted: 2024/12/02
Sponsor:
University Hospital,...
Phase 4
Recruiting
Posted: 2024/03/27
Sponsor:
Women and Infants Ho...

FDA Approved Products

Gentamicin Sulfate in Sodium Chloride
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:100 mg in 100 mL
Approved: 2016/07/07
NDC:0338-0505
Gentamicin Sulfate
Manufacturer:Teligent Pharma, Inc.
Route:TOPICAL
Strength:1 mg in 1 g
Approved: 2019/09/10
NDC:52565-090
Gentamicin Sulfate in Sodium Chloride
Manufacturer:Baxter Healthcare Corporation
Route:INTRAVENOUS
Strength:80 mg in 50 mL
Approved: 2016/07/07
NDC:0338-0509
Gentak
Manufacturer:A-S Medication Solutions
Route:OPHTHALMIC
Strength:3 mg in 1 g
Approved: 2012/03/02
NDC:50090-4770
Gentamicin
Manufacturer:REMEDYREPACK INC.
Route:INTRAVENOUS, INTRAMUSCULAR
Strength:40 mg in 1 mL
Approved: 2024/03/26
NDC:70518-3628

Singapore Approved Products

BEPROGENT CREAM
Manufacturer:HOE PHARMACEUTICALS SDN BHD
Form:CREAM
Strength:0.1% w/w
Online:Yes
Approved: 1996/11/28
Approval:SIN09020P
TRI-MICON CREAM
Manufacturer:BEACONS PHARMACEUTICALS PTE. LTD.
Form:CREAM
Strength:0.1% w/w
Online:Yes
Approved: 1999/01/26
Approval:SIN10705P
B-TASONE-G CREAM
Manufacturer:BEACONS PHARMACEUTICALS PTE. LTD.
Form:CREAM
Strength:0.3% w/w
Online:Yes
Approved: 1990/02/26
Approval:SIN04424P
ANTASONE CREAM
Manufacturer:SHIN POONG PHARMACEUTICAL CO LTD
Form:CREAM
Strength:1.214mg equiv to 1 mg
Online:Yes
Approved: 1988/06/25
Approval:SIN02144P
GENTRISONE CREAM
Manufacturer:SHIN POONG PHARMACEUTICAL CO LTD
Form:CREAM
Strength:1 mg/g
Online:Yes
Approved: 1990/08/03
Approval:SIN04989P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath